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RUNX1/ETO blocks selectin-mediated adhesion via epigenetic
silencing of PSGL-1
K Ponnusamy1,2, N Kohrs3, A Ptasinska4, SA Assi4, T Herold5, W Hiddemann5, J Lausen3, C Bonifer4, R Henschler1,2 and C Wichmann1,3
RUNX1/ETO (RE), the t(8;21)-derived leukemic transcription factor associated with acute myeloid leukemia (AML) development,
deregulates genes involved in differentiation, self-renewal and proliferation. In addition, these cells show differences in cellular
adhesion behavior whose molecular basis is not well understood. Here, we demonstrate that RE epigenetically silences the gene
encoding P-Selectin Glycoprotein Ligand-1 (PSGL-1) and downregulates PSGL-1 expression in human CD34+ and murine lin−
hematopoietic progenitor cells. Levels of PSGL-1 inversely and dose-dependently correlate with RE oncogene levels. However, a
DNA-binding defective mutant fails to downregulate PSGL-1. We show by ChIP experiments that the PSGL-1 promoter is a direct
target of RE and binding is accompanied by high levels of the repressive chromatin mark histone H3K27me3. In t(8;21)+ Kasumi-1
cells, PSGL-1 expression is completely restored at both the mRNA and cell surface protein levels following RE downregulation with
short hairpin RNA (shRNA) or RE inhibition with tetramerization-blocking peptides, and at the promoter H3K27me3 is replaced by
the activating chromatin mark H3K9ac as well as by RNA polymerase II. Upregulation of PSGL-1 restores the binding of cells to
P- and E-selectin and re-establishes myeloid-specific cellular adhesion while it fails to bind to lymphocyte-specific L-selectin. Overall,
our data suggest that the RE oncoprotein epigenetically represses PSGL-1 via binding to its promoter region and thus affects the
adhesive behavior of t(8;21)+ AML cells.
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INTRODUCTION
RUNX1/ETO (RE), the t(8;21)-derived fusion protein, is present
in 12% of de novo acute myeloid leukemia (AML) cases and
up to 40% of M2 subtype AMLs according to the French–
American–British classification.1 Recently, a truncated form
of RE (REtr), which lacks the C-terminal N-CoR/SMRT-interacting
domain, has been identified, recapitulating a naturally
occurring highly leukemogenic splice variant RE9a observed in
AML patients.2,3 RE harbors the DNA-binding domain of RUNX1
fused to the nearly entire nuclear co-repressor ETO protein.
RE heterodimerizes with CBFβ for efficient binding to DNA in
complex with other transcription regulators that causes
deregulation of normal myelopoiesis.1,4 The ETO region
acts as a dominant repressor of RUNX1 target genes by
recruiting nuclear co-repressors such as N-CoR, SMRT, mSIN3A
and histone deacetylases.5–8 RE directly represses several
targets such as PU.1, CEBPα, microRNA-223, granulocyte–macro-
phage colony-stimulating factor and neutrophil elastase.9–12
However, RE can also activate the transcription of certain genes
such as p21/WAF/Cip1, ID1 and EGR1 via recruitment of p300.12
Likewise, RE epigenetically deregulates genes involved in pro-
liferation, self-renewal and differentiation of hematopoietic stem
and progenitor cells, which results in a differentiation block at the
myeloblastic stage.13
Adhesion molecules have a pivotal role in hematopoietic stem
and progenitor cell trafficking and steady-state hematopoiesis.14
The expressions of hematopoietic stem and progenitor cell
homing receptors such as VLA-4, LFA-1, P-Selectin Glycoprotein
Ligand-1 (PSGL-1) and CD44 are frequently deregulated in
malignant hematopoietic cells.15–18 Moreover, expressions of
CD44, VLA-4 and LFA-1 have been found to be directly regulated
by RE.15,17,19 The transmembrane protein PSGL-1 is a 220-kDa
disulfide-linked homodimeric sialomucin expressed on the surface
of activated endothelial cells, myeloid cells and lymphoid cells.20 It
is the principal ligand for P (platelet)-selectin; however, under
physiological flow conditions, it also binds to E (endothelial)- and L
(leukocyte) selectin.21,22 Selectin recognition is critically depen-
dent on post-translational modifications such as sialylation,
fucosylation and O-glycosylation of PSGL-1.20,23,24 PSGL-1 also
harbors binding sites for the chemokines CCL19 and CCL21 and
efficiently regulates the homing of T cells to secondary lymphoid
organs.25,26 The PSGL-1/P-selectin interaction contributes to the
rolling of hematopoietic cells on endothelial cells followed by
migration into tissues, thereby regulating immunity and steady-
state hematopoiesis.21,27,28 PSGL-1-deficient leukocytes show
impaired tethering to and rolling on P- and E-selectin in vivo.29
Furthermore, blocking the N-terminal region of PSGL-1 with
monoclonal antibodies abolishes leukocyte rolling on P- and
L-selectin.30
In this report, we show that RE directly interacts with the PSGL-1
promoter region and epigenetically represses PSGL-1 in hemato-
poietic progenitor cells. The result of this repression is an
impediment of cellular adhesion, which is completely restored
after depletion of RE. This demonstrates that the deregulation of
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PSGL-1 expression and other adhesion molecules is an important
feature of t(8;21)+ AML.
RESULTS
PSGL-1 is absent in t(8;21)+ AML cells
To identify adhesion molecules regulated by RE, we analyzed the
adhesion molecule expression pattern of Kasumi-1 cells compared
with human CD34+ cells obtained from peripheral blood
apheresis of healthy donors (Figure 1a). The integrin LFA-1
(CD11a, ITGαL) has been reported as a directly repressed RE target
gene15 and was found to be expressed at low levels in Kasumi-1
cells (Figure 1a). Differences were also observed for ITGα5, ITGß1,
ICAM-1, CXCR4, CXCR7, ITGß7 and L-selectin. Most strikingly,
Kasumi-1 cells express barely detectable levels of the sialomucin
PSGL-1 (Figures 1a and b). PSGL-1 was also identified as a
potential RE target via genome-wide chromatin immunoprecipita-
tion (ChIP)-sequencing experiments with Kasumi-1 cells and t
(8;21)+ patient material.31 In agreement with our observations, a
publically available gene array database has revealed low PSGL-1
expression levels in t(8;21)+ primary leukemic cells compared with
healthy counterparts (Figure 1c).32 A further analysis of a large
AML gene array data set categorized by karyotypes also revealed
low PSGL-1 expression in t(8;21)+ samples (Figure 1d).
RE downregulates PSGL-1 expression in hematopoietic
progenitor cells
To understand whether RE directly regulates PSGL-1, we over-
expressed REtr in various hematopoietic progenitor cells via
lentiviral vector transduction. On day 4 after transduction, PSGL-1
expression levels in hematopoietic progenitor cells were analyzed
using flow cytometry. REtr downregulated PSGL-1 cell surface
expression in mobilized human hematopoietic CD34+ progenitor
cells compared with mock-transduced control cells (Figure 2a).
REtr also downregulated PSGL-1 in murine lineage-negative bone
marrow-derived primary hematopoietic progenitor (lin− mBM)
cells and in a factor-dependent multipotent FDCP-mix progenitor
cell line (Figures 2b and c). Likewise, full-length RE repressed
PSGL-1 expression in lin− mBM cells (Figure 2d). Together, these
data indicate that RE is a potent repressor of PSGL-1 expression in
hematopoietic progenitor cells. We co-expressed enhanced green
fluorescent protein (eGFP) from the same construct and gated
cells expressing eGFP at low, medium and high levels to elucidate
the dosage dependency of REtr on PSGL-1 regulation. Compared
with empty vector-transduced cells, the expression levels
of REtr inversely correlated with PSGL-1 levels (Figure 2e).
Likewise, dose-dependent downregulation of PSGL-1 by REtr
was also observed in primary human CD34+ progenitor cells
(Supplementary Figure 1). Next, we examined whether RE required
its DNA-binding function to regulate PSGL-1 expression. The
DNA-binding-defective mutant REtr(L148D)33,34 completely failed
to regulate PSGL-1 in FDCP-mix cells (Figure 2f). Overall, we
found that RE downregulates PSGL-1 expression in hemato-
poietic progenitor cells in a DNA-binding- and dose-dependent
manner.
Depletion and inhibition of RE induce complete re-expression of
PSGL-1 in t(8;21)+ Kasumi-1 cells
To investigate whether inhibition of RE also affects PSGL-1
expression in a transformed RE-dependent human leukemic cell
line, a short hairpin RNA (shRNA) against the breakpoint region of
RE (shRE)19 was expressed in the RE-dependent cell line Kasumi-1.
Compared with control cells expressing a mismatch control RNA
(scr), RE depletion completely restored PSGL-1 levels in Kasumi-1
cells on day 4 post transduction, as observed in mobilized CD34+
cells (Figure 3a). PSGL-1 upregulation occurred within 24 h after
lentivirus-mediated RE knockdown with increasing cell surface
expression levels over time (Figure 3b). As tetramerization of RE is
essential for its oncogenic function, we employed peptide-
mediated interruption of RE tetramerization.34,36 NLS-tagged
NHR2 sequences were lentivirally overexpressed. NHR2 peptides
are proposed to bind to the RE NHR2 domain, thereby blocking
oligomerization of RE molecules and inhibiting its transcriptional
and transforming properties.34,37 Indeed, disruption of RE
oligomerization using N89 peptides also activated PSGL-1 expres-
sion on the surface of Kasumi-1 cells to a similar extent (Figures 3c
and d), thereby further supporting the notion that PSGL-1 is a
target gene of RE.
RE interacts with and induces epigenetic modifications at the
promoter region of PSGL-1
As lentivirus-mediated expression of RE-inhibiting peptides
induced high mRNA levels of PSGL-1 (Figure 4a), we next
investigated the connection between RE binding and PSGL-1
expression and examined PSGL-1 genomic sequences for the
presence of potential RUNX1-binding motifs (TGT/CGGT) in silico.
Four clusters of RUNX1-binding motifs were identified at the
promoter and within intronic regions (Figure 4b; Supplementary
Figure 3a) together with Sp1 and ETS transcription factor-binding
motifs within the predicted promoter region. ChIP-sequencing
experiments using an ETO antibody31 confirmed several RE-
binding sites as well as RUNX1 sites upstream of exon 1 of the
PSGL-1 genomic sequences, which disappeared after RE knock-
down (Figure 4c). These data were verified by manual ChIP
locating the RE-binding motif within the PSGL-1 promoter region
at − 619 bp (cluster 1; Figure 4d; Supplementary Figures 2 and 3b).
Among other adhesion molecules, PSGL-1 was identified
also in human primary t(8;21)+ AML patient samples (see
Supplementary Figure 4).31,35 As RE has been shown to induce
epigenetic changes to repress its target genes,31 we examined the
RE-binding sites for the presence of several active and repressive
histone marks including the repressive H3K27me3 chromatin
mark. This revealed H3K27 trimethylation of the PSGL-1 promoter
upstream of exon 1 (Figure 4e). siRNA-mediated depletion of RE
led to an increase in the binding of RUNX1 at the RE-binding sites
with a concomitant increase in histone acetylation and RNA POLII
within the predicted PSGL-1 promoter region (Figure 4c;
Supplementary Figure 3b). Overall, our data suggest that RE
binding epigenetically represses PSGL-1 expression.
RE-depleted Kasumi-1 cells gain potential to bind to P- and
E-selectin under shear stress
PSGL-1 is the principal ligand for P-selectin and, to a lesser extent,
E-selectin20 but not L-selectin. We therefore investigated the
consequences of RE inactivation for cell adhesion. The transduc-
tion of N89 inhibitor peptide led to a profound upregulation of
binding of Kasumi-1 cells to P-selectin-coated beads and, to a
lesser extent, E-selectin as measured via flow cytometry. However,
no binding to L-selectin was observed (Figures 5a and b). Likewise,
adhesion of N89-expressing Kasumi-1 cells was highly increased
on P-selectin and, to a lesser extent, E-selectin-coated surfaces
(Figures 5c and d). Furthermore, the capacity of shRE-expressing
Kasumi-1 cells to interact with P-selectin-coated surfaces was
assessed under shear stress. Before conducing the experiments,
proper re-expression of PSGL-1 on the surface of shRE-transduced
Kasumi-1 cells was confirmed (Figure 5e). Indeed, the rolling
efficiency of shRE-treated Kasumi-1 cells on P-selectin-coated
surface was also increased under shear stress at 2 dynes/cm2,
whereas control cells showed only weak or no interaction
(Figure 5f). Moreover, shRE-expressing Kasumi-1 cells were firmly
arrested following rolling on P-selectin-coated surfaces
(Figure 5g), thereby suggesting a strong interaction between the
shRE-treated Kasumi-1 cells and P-selectin.
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DISCUSSION
Our study adds important molecular details to previous studies
demonstrating that the expression of RE perturbs the regulation of
members of the adhesion gene family17,19 by describing the
consequences of RE binding for the regulation of PSGL-1,
encoding for a mucin-like glycoprotein crucially involved in
Figure 1. Expression levels of PSGL-1 in t(8;21)+ leukemic cells. (a) Cell surface expression patterns of adhesion molecules in Kasumi-1 cells
and human hematopoietic CD34+ cells as assessed via flow cytometry (n= 3). (b) Histogram of cell surface expression levels of PSGL-1 in t
(8;21)+ Kasumi-1 cells and healthy donor-derived human CD34+ cells as analyzed via flow cytometry. (c) Expression levels of PSGL-1 mRNA in
patient-derived primary leukemic cells based on microarray data analysis.32 (d) PSGL-1 mRNA expression in patient-derived primary leukemic
cells categorized by karyotypes. Data are shown as the mean± s.e.m.
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Figure 2. Regulation of PSGL-1 expression in enriched hematopoietic progenitor cells. Expression of PSGL-1 in (a) human primary
hematopoietic CD34+ progenitor cells, (b) lin− mBM cells and (c) FDCP-mix cells as analyzed via flow cytometry on day 4 post transduction.
(d) PSGL-1 levels of RE- and REtr-expressing lin− mBM cells on day 4 post transduction. (e) After transduction different levels of eGFP
expression in FDCP-mix cells were gated as population 1, 2 and 3. PSGL-1 expression levels were measured for the corresponding gated cells.
The data show representative results obtained out of three experiments. (f) A representative histogram of PSGL-1 expression in a DNA-
binding defective mutant form of REtr(L148D)-transduced cells. *Po0.05. n= 3.
Figure 3. Effect of RE inhibition on PSGL-1 expression in Kasumi-1 cells. (a) Histogram and percentage of positive cells displaying cell surface
PSGL-1 expression analyzed via flow cytometry in Kasumi-1 cells transduced with scramble control (scr) and shRNA against the breakpoint
region of RE (shRE). (b) Cell surface levels of PSGL-1 expression over time after shRE transduction in Kasumi-1 cells. (c, d) Cell surface
expression levels of PSGL-1 in Kasumi-1 cells transduced with lentiviral vectors expressing control peptides (CP), N89 peptides and eGFP as
marker. Data shown as the mean± s.e.m. ***Po0.001. n= 3.
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cellular adhesion. Together with the findings that in RE-expressing
cells CD44 and VLA-4 are upregulated and CD11a is down-
regulated, this suggests that adhesion molecules are important
targets for the establishment of a t(8;21)-specific cellular
phenotype. A similar adhesion molecule pattern is found on
highly mobile early hematopoietic myeloblasts in normal bone
marrow. CD44 is broadly upregulated in AML and contributes to
therapy relapse and has therefore been suggested as a potential
therapeutic target.17,38 CD11a is highly expressed on M4 and M5
leukemias, whereas M0 to M3 leukemias express the protein at
low to intermediate levels.39 Similarly, PSGL-1 has been suggested
as a marker to distinguish different types of AMLs.40 PSGL-1 is also
involved in thymic settling of hematopoietic progenitors41,42 as RE
expression and PSGL-1 downregulation appear to be incompatible
with T-cell progenitor homing to the thymus in spite of the
presence of the fusion protein in myeloid cells and B cells from
AML patients with t(8;21),43 indicating that the downregulation of
this gene has dramatic consequences for cellular behavior, the
most likely being an increased mobility of leukemic cells.
Consistent with this idea, PSGL-1 is constantly downregulated in
a large cohort of primary human AML M2 t(8;21)+ leukemia cells
compared with bone marrow cells from healthy individuals.
In an independent gene expression analysis, PSGL-1 was most
prominently repressed in t(8;21)+ AML leukemias compared
with various AML subgroups categorized by karyotypes,
indicating that repression of this gene may be a core feature of
core-binding factor leukemias. PSGL-1 mRNA has indeed been
found to be downregulated in t(12;21)+ AMLs expressing the
fusion protein TEL/RUNX1, which has also been described as a
dominant transcriptional repressor of RUNX1 target genes,44
suggesting that this fusion protein targets the same cis-regulatory
elements.
To bind P- and E-selectin, PSGL-1 requires core 2 O-linked
glycans that are sialylated and fucosylated. Interestingly, the sole
derepression of PSGL-1 was fully sufficient for its adhesion
function, thereby suggesting that PSGL-1-modifying components
were activated in RE-depleted Kasumi-1 and hematopoietic
progenitor cells. P- and E-selectin are responsible for adhesion
of hematopoietic cells to endothelial cells.45 Interestingly,
L-selectin, which is preferentially expressed on leukocytes, was
not bound by upregulated PSGL-1 upon RE inhibition. These
observations indicate that RE+ progenitors may have a reduced
affinity to the vascular niche within the bone marrow.
Azab et al.18 have found increased PSGL-1 levels on malignant
hematopoietic cells derived from multiple myeloma patients and
showed that PSGL-1 has a critical role in the survival and
development of multiple myeloma cells within the bone
marrow.46 This stromal interaction was responsible for disease
progression and drug resistance. Low-level PSGL-1 expression has
an impact on the proliferation capacity of early hematopoietic
stem cells as adhesion to P-selectin inhibits in vitro proliferation of
human hematopoietic stem cells triggered by early acting growth
factors.47 Furthermore, PSGL-1 has a role in stem cell anchorage
within the bone marrow niche.48 RE-mediated repression of
PSGL-1 may therefore have an impact on stem cell quiescence as
well as leukemic engraftment. This is suggested by studies with
PSGL-1-deficient BCR/ABL cells, which are impaired in engraftment
potential in a mouse transplantation model.49 PSGL-1 deficiency
also augments the mobilization of hematopoietic progenitor cells
into the peripheral blood,50 thereby suggesting that RE-mediated
PSGL-1 repression reduces cell adhesion in t(8;21)+ hematopoietic
progenitor cells in the bone marrow. This may partially explain the
favorable response of core-binding factor leukemias toward
chemotherapy treatment.
Figure 4. Transcriptional regulation of PSGL-1 expression in Kasumi-1 cells. (a) Expression levels of PSGL-1 mRNA in Kasumi-1 cells transduced
with control and N89 peptides as assessed via quantitative PCR. (b) In silico analysis shows RUNX1 recognition motifs in various regions of the
PSGL-1 gene sequences and the presence of SP1 and ETS transcription factor recognition motifs at the PSGL-1 promoter region. (b, top)
Alignment of the RUNX1 recognition motif (TGT/c GGT) with the promoter sequences of the PSGL-1 gene. (c) ChIP-sequencing data, which
show RUNX1 and RE interaction with the promoter region of PSGL-1. SiRNA-mediated downregulation of RE facilitated RNA POLII-binding and
H3K9ac marks at the upstream region of the PSGL-1 gene. (d) Interaction of RE with the predicted RUNX1-binding clusters of the PSGL-1 gene
as analyzed via quantitative PCR, which amplified the ChIP DNA obtained against the RE-binding region. (e) H3K27me3 modification of the
PSGL-1 promoter region examined via ChIP analysis. The promoter region of GAPDH was used as negative control and the heterochromatin
region of chromosome 18 (hetero chr 18) as positive control. Data shown as the mean± s.e.m. *Po0.05, ***Po0.001.
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Taken together, our data demonstrate a direct link between RE-
binding and the pattern of expression of adhesion molecules in
leukemic cells that will be of diagnostic relevance both as
biomarker, but also for the evaluation of RE inhibitors that are
currently under development.
MATERIALS AND METHODS
Cells, cell culture, viral production and viral transduction
FDCP-mix cells were cultured in IMDM medium (PAA Lab, Colbe, Germany)
supplemented with horse serum (Gibco, Darmstadt, Germany) and murine
IL3 (10 ng/ml; R&D Systems, Wiesbaden, Germany). Kasumi-1 cells were
cultured in RPMI medium (Gibco) supplemented with 20% FCS (fetal calf
serum; PAN Biotech, Aidenbach, Germany). Lin− mBM cells were cultured
in StemSpan medium (StemCell Tech, Cologne, Germany) supplemented
with murine IL3 (10 ng/ml), murine IL6 (50 ng/ml) and murine stem cell
factor (50 ng/ml). Human CD34+ cells were cultured in StemSpan medium
supplemented with human IL3 (10 ng/ml), human SCF (20 ng/ml), human
IL6 (20 ng/ml), human FLT3L (20 ng/ml), human thrombopoietin (20 ng/ml)
and human granulocyte–macrophage colony-stimulating factor (20 ng/ml).
Lentiviral particles were produced using the calcium phosphate co-
precipitation method. Briefly, 5.8 × 106 HEK-293 T cells were seeded in a 10-
cm2 tissue culture dish (Cellstar, Frickenhausen, Germany) and incubated
at 37 °C in a humidified CO2 incubator. Next day, the co-transfection mix
was prepared and distributed over the cells. Fresh medium was
replenished 6 h after transfection. Finally, the viral supernatants were
collected 48 h after transfection. Viral particles were then transduced into
the cells on retronectin (50 μg/ml)-coated non-tissue culture plates.
Retroviral vectors and shRNA against RE
Lentiviral LeGO vectors (http://www.lentigo-vectors.de/vectors.htm) co-
expressing eGFP as a marker gene were described in our previous
publication.19 Peptide-mediated interruption of RE tetramerization was
performed using the NHR2-inhibitor peptide described before.37 Efficacy
of the shRNA against the RE breakpoint sequences was recently
demonstrated.19
Figure 5. Functionality of restored PSGL-1 in shRE- and N89-treated Kasumi-1 cells. (a) Histograms of binding ability of Kasumi-1 cells
transduced with CPs or N89 peptides to P-, E- and L-selectin as analyzed via flow cytometry and (b) percentage of corresponding positive cells.
(c) Adhesion of CP- and N89-transduced Kasumi-1 cells on P-, E- and L-selectin-coated surfaces and (d) the corresponding quantitative values.
(e) Cell surface expression levels of PSGL-1 in scramble (scr)- and shRE-transduced Kasumi-1 cells as analyzed via flow cytometry. (f) Rolling
efficiency of shRE-transduced Kasumi-1 cells followed by (g) cell arrest on a P-selectin-coated surface under shear stress (2 dynes/cm2).
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Isolation of human CD34+ and lin− mBM cells
Total murine bone marrow hematopoietic cells were harvested from 6- to
8-week-old Bl6 mice after killing via cervical dislocation under anesthetic
conditions (isoflurane inhalation). The lin− mBM cells were enriched using
the mouse lineage depletion kit (Miltenyi Biotec, Cologne, Germany).
Mobilized human CD34+ bone marrow cells were obtained from healthy
donors following their informed consent according to the institutional
review board-approved protocol (DRK Blood donor service, Frankfurt am
Main, Germany). Furthermore, the peripheral blood mononuclear cells
were isolated via biocoll separation (Biochrom, Berlin, Germany). There-
after, human CD34+ cells were enriched using a MACS CD34+ cell isolation
kit (Miltenyi Biotec).
Flow cytometry
To analyze expression of cell surface adhesion molecules, 1 × 105 cells were
prepared in 0.5% bovine serum albumin (100 μl) and incubated with FcR
block (2 μl) for 10 min at room temperature. Thereafter, the cells were
washed twice with 1x PBS. Subsequently, the cells were stained with
fluorescent-labeled antibodies (1 μl antibody/100 μl cell suspension) and
incubated for 30min at 4 °C. Next, the cells were washed and measured via
multicolor flow cytometry. The data were analyzed using FCS express and
FlowJo software (Flowjo LLC, Ashland OR) under the institute’s license.
Quantitative PCR (qPCR)
PSGL-1 expression at the mRNA level was analyzed via quantitative PCR.
Briefly, 105 − 106 cells were washed twice with ice-cold 1x PBS and
centrifuged at 2000 r.p.m., at 4 °C for 5 min. The cell pellets were collected
and processed for total RNA isolation using an RNasy kit (Qiagen, Hilden,
Germany). Subsequently, the retrieved total RNA was treated with DNase I
at 37 °C for 30min. Thereafter, the enzymatic reaction was inactivated at
65 °C for 10min. Furthermore, 500 ng of RNA was reverse-transcribed into
cDNA for 1 h at 50 °C using oligo-dT primer and superscript III reverse
transcriptase. Finally, 5% of the transcribed cDNA was used for gene
expression analysis via qPCR using TaqMan reaction mixtures. The relative
mRNA expression levels were calculated for each sample as follows: the
mean of PSGL-1 expression levels divided by the mean of GAPDH
expression levels.
Selectin-binding assay, cell rolling and arrest under shear stress
Recombinant P-, E- and L-selectin human chimeras (3 μg/ml) were
conjugated with biotin (eBioscience, Frankfurt, Germany) followed by
streptavidin (BD Pharmingen, Frankfurt, Germany). Transduced Kasumi-1
cells were incubated with the biotin/streptavidin-conjugated selectins and
analyzed for selectin binding using a standard flow cytometry protocol. For
cell adhesion, transduced Kasumi-1 cells were seeded on P-, E- and
L-selectin (3 μg/ml)-coated non-tissue culture plates. After 2 h incubation
at 37 °C, we gently washed the cells three times with 1x PBS. Then, adhered
cells were quantified. The rolling and firm arrest efficiencies of transduced
Kasumi-1 cells on its ligand P-selectin were assessed under shear stress.
Briefly, the flow chamber slides were coated with P-selectin (5 μg/ml) for
30min at room temperature. The P-selectin-coated surface was
then incubated with 2% bovine serum albumin for 10min. Next, 105 cells
were injected into the HBSS++ medium, which flows on the coated
surface under the shear stress 2 dynes/cm2 applied simultaneously. Finally,
the rolling and arrested cells on the P-selectin-coated surface were
quantified.
ChIP and ChIP-sequencing assay
DNA-binding ability of RE on the PSGL-1 gene was assessed via ChIP assay.
Briefly, 107 Kasumi-1 cells were fixed. Protein/DNA complexes were
crosslinked by adding 0.75% paraformaldehyde. Thereafter, the cross-
linking reaction was terminated using 125mM glycine. Subsequently, the
cells were lysed using ChIP lysis buffer for 45min at 4 °C after washing the
cells in ice-cold 1x PBS. Meanwhile, 50 μl protein G beads were blocked
with 100× salmon sperm single-strand DNA (1%) in RIPA buffer at 4 °C for
30min. After cell lysis, the cells were sonicated for 2 min to shear the
chromatin to less than 1 kb in size. Next, 20–25 μg of sheared chromatin
was incubated without the beads as an input control or with the pre-
blocked protein G beads containing isotype (3 μg), ETO (5 μg), RNA
polymerase II (2.5 μg) or H3K27me3 (2.5 μg) antibodies. After overnight
incubation at 4 °C, the beads were collected under the magnetic field. The
ChIP DNA was then eluted after reverse-crosslinking the chromatin using
ChIP elution buffer. The RNA was degraded with RNase, and the protein
was degraded with proteinase K. The DNA was isolated using a ChIP DNA
isolation kit (Zymo research corp, Freiburg, Germany). Finally, the isolated
DNA was amplified for PSGL-1 gene sequences via qPCR. The Ct values
were calculated for fold enrichment compared with the isotype control or
input values. The forward (F) and reverse (R) primer sequences are as
follows: cluster 1: ACCCTCACTTCTCTGGGTTCT (F), CACTCCATCCAGGTGTC
ACT (R); cluster 2: GCAACATGGTGAAACCTCGT (F), GAGTGCAGTGGCAC
AATCTC (R); cluster 3: ATAACTTGAGGCCAGGAGTTTG (F), CCGGGTTCAAGTG
ATTCTCC (R) and cluster 4: CCCAGACCACATCTCTGTGA (F), GGTACATGTG
GCCCTTGC (R). The GAPDH and heterochromatin 18 primer sequences
have been previously described.31 For the ChIP-seq experiments, anti-ETO
antibody (Santa Cruz, sc-9737X, Santa Cruz Biotechnology, Wembley, UK)
was used.31 The RUNX1 antibody (Abcam, ab23980, Cambridge, UK)
recognizes the C-terminal domain of RUNX1, which is absent in the fusion
protein. RE knockdown was archived using siRNA.32
AML microarray set characteristics
Overall, 533 patients were treated within the AMLCG-99 trial
(NCT00266136) and 29 patients within the M3-AMLCG study. 562
Microarrays: 140 Affymetrix HGU 133 2.0 plus and 422 A&B Set. A minimum
of 20 metaphase cells were analyzed to consider the diagnosis of a normal
karyotype (CN-AML). A complex karyotype was defined as the presence of
three or more chromosome abnormalities in the absence of t(8;21), inv(16),
t(16;16), t(15;17), t(9;11), t(v;11)(v;q23); inv(3), t(3;3) or t(6;9). Pretreatment
bone marrow samples were prepared after Ficoll gradient centrifugation.
Total RNA was extracted from 562 bone marrow samples as described
previously51 and analyzed using Affymetrix HG-U133 A/B and 2.0 plus
oligonucleotide microarrays (Affymetrix, Santa Clara, CA, USA). Hybridiza-
tion and image acquisition followed official Affymetrix protocols. No cell
sorting was performed. For probes to probe set annotation, we used
custom chip definition files (CDFs) based on GeneAnnot version 2.0,
synchronized with GeneCards Version 3.04 (available at http://www.xlab.
unimo.it/GA_CDF/).52 These CDFs decrease the total number of probe sets
(one probe set per gene), and potentially increase the specificity of the
analyses by eliminating cross-hybridizing probes (probes are restricted by
sequence specificity). Data normalization was performed using the Robust
Multichip Average method as described before.53 Only the 17 389-probe
sets present both on the A, B chips and the 2.0 plus chips were included in
the analysis. Some probe sets on the A, B chips tend to have lower mean
signal levels and higher s.d.'s than the corresponding probe sets on the
Plus 2.0 chips. To eliminate this batch effect resulting from the different
chip designs, we performed a second normalization using an empirical
Bayesian method.
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